AP Biosciences Inc
6945.TWO
Taipei Exchange126.50
TWD
- -
- -
AP Biosciences Inc
6945.TWO
(Taipei Exchange)
Recent
price
126.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- AP Biosciences Inc (6945.TWO) is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of bispecific antibodies and protein drugs targeting unmet medical needs in oncology and immune diseases. Founded in 2013 and headquartered at 11F.-2, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City, Taiwan, the company leverages proprietary platforms including the OmniMab Naïve Antibody Phage Display Library and the T-cube symmetrical bispecific antibody platform to design fully human antibodies that simplify manufacturing and enhance immune responses in solid tumors. Its pipeline features lead candidates such as AP402 (4-1BB x p95HER2 bispecific antibody) in Phase 1/2 trials for HER2-positive tumors; AP203 (4-1BB x PD-L1) in Phase 1/2 for head and neck squamous cell carcinoma; AP505/B1962 (PD-L1 x VEGF, also known as IBI302 licensed to Innovent and Tasly) advancing to Phase 2/3 for neovascular age-related macular degeneration and solid tumors; AP601 in Phase 1 for solid tumors; and Efdamrofusp alfa (C3b x C4B x CR1 x VEGF fusion protein) in Phase 2 for wet AMD, alongside earlier-stage monoclonal antibodies and fusion proteins focused on cancer immunotherapy, complement inhibition, and angiogenesis modulation. AP Biosciences operates primarily in Taiwan with clinical trials in Australia, China, and partnerships granting Greater China rights for key assets; it functions as a subsidiary of AbProtix, Inc. and received majority equity investment from OBI Pharma in 2018. Recent developments include closing a $38 million Series D funding round in June 2024 to support pipeline advancement; approvals in 2024-2025 from Australia's TGA and HRECs for Phase 1/2 trials of AP402 and Phase 1 of AP601 with patient dosing underway; Phase 2 initiation of AP505/B1962 in China by partner Tasly Pharmaceuticals; a September 2025 partnership with OBI Pharma to co-develop bispecific antibody-drug conjugates; listing on the Taipei Exchange Emerging Stock Board in 2023; and key U.S. and international patents granted for its T-cube platform and AP505.